JP2020520963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520963A5 JP2020520963A5 JP2019564822A JP2019564822A JP2020520963A5 JP 2020520963 A5 JP2020520963 A5 JP 2020520963A5 JP 2019564822 A JP2019564822 A JP 2019564822A JP 2019564822 A JP2019564822 A JP 2019564822A JP 2020520963 A5 JP2020520963 A5 JP 2020520963A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- hours
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 206010011971 Decreased interest Diseases 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023009149A JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510481P | 2017-05-24 | 2017-05-24 | |
| US62/510,481 | 2017-05-24 | ||
| US15/933,673 US20180338959A1 (en) | 2017-05-24 | 2018-03-23 | Treatment of depressive disorders |
| US15/933,673 | 2018-03-23 | ||
| PCT/US2018/033848 WO2018217718A1 (en) | 2017-05-24 | 2018-05-22 | Treatment of depressive disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009149A Division JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520963A JP2020520963A (ja) | 2020-07-16 |
| JP2020520963A5 true JP2020520963A5 (enExample) | 2021-07-26 |
Family
ID=64395877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564822A Pending JP2020520963A (ja) | 2017-05-24 | 2018-05-22 | 抑うつ障害の処置 |
| JP2023009149A Withdrawn JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009149A Withdrawn JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20180338959A1 (enExample) |
| EP (2) | EP3630065A4 (enExample) |
| JP (2) | JP2020520963A (enExample) |
| KR (1) | KR20200018485A (enExample) |
| CN (2) | CN110996910A (enExample) |
| AU (1) | AU2018272819A1 (enExample) |
| CA (1) | CA3064299A1 (enExample) |
| IL (1) | IL270781A (enExample) |
| MX (1) | MX393452B (enExample) |
| WO (1) | WO2018217718A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2019213286A1 (en) * | 2018-05-02 | 2019-11-07 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| BR112021009944A2 (pt) | 2018-11-21 | 2021-08-17 | Certego Therapeutics Inc. | gaboxadol para reduzir risco de suicídio e alívio rápido de depressão |
| AU2020223284A1 (en) | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| KR102085938B1 (ko) * | 2019-11-04 | 2020-03-06 | 한국메탈실리콘 주식회사 | 실리콘 복합체 제조방법 |
| JP2023526439A (ja) | 2020-05-20 | 2023-06-21 | セルテゴ セラピューティクス インコーポレイテッド | 精神障害の処置のための環重水素化ガボキサドールおよびその使用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| EP2145620A3 (en) * | 2003-06-25 | 2010-03-17 | H. Lundbeck A/S | Gaboxadol for treating depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| AU2005229493A1 (en) | 2004-04-02 | 2005-10-13 | H. Lundbeck A/S | Treatment of impaired respiratory function with gaboxadol |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| US10628156B2 (en) * | 2013-07-09 | 2020-04-21 | Texas Instruments Incorporated | Vector SIMD VLIW data path architecture |
| RS62006B1 (sr) * | 2014-06-06 | 2021-07-30 | Ovid Therapeutics Inc | Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice |
| MX391708B (es) * | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| CA3146737A1 (en) * | 2019-07-15 | 2021-01-21 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
-
2018
- 2018-03-23 US US15/933,673 patent/US20180338959A1/en not_active Abandoned
- 2018-05-22 AU AU2018272819A patent/AU2018272819A1/en not_active Abandoned
- 2018-05-22 KR KR1020197038042A patent/KR20200018485A/ko not_active Ceased
- 2018-05-22 JP JP2019564822A patent/JP2020520963A/ja active Pending
- 2018-05-22 CA CA3064299A patent/CA3064299A1/en active Pending
- 2018-05-22 EP EP18805653.5A patent/EP3630065A4/en not_active Withdrawn
- 2018-05-22 EP EP21195602.4A patent/EP3939587A1/en not_active Withdrawn
- 2018-05-22 MX MX2019014024A patent/MX393452B/es unknown
- 2018-05-22 CN CN201880048161.4A patent/CN110996910A/zh active Pending
- 2018-05-22 CN CN202210735249.1A patent/CN115105499A/zh active Pending
- 2018-05-22 WO PCT/US2018/033848 patent/WO2018217718A1/en not_active Ceased
- 2018-12-18 US US16/223,356 patent/US20190117633A1/en not_active Abandoned
-
2019
- 2019-11-20 IL IL270781A patent/IL270781A/en unknown
-
2020
- 2020-02-19 US US16/794,354 patent/US20200179351A1/en not_active Abandoned
-
2021
- 2021-08-18 US US17/405,525 patent/US20210379028A1/en not_active Abandoned
-
2023
- 2023-01-25 JP JP2023009149A patent/JP2023061957A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520963A5 (enExample) | ||
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| Ehrlich et al. | Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study | |
| JP2014515373A5 (enExample) | ||
| JP2015518897A5 (enExample) | ||
| JPWO2006035876A1 (ja) | 関節リウマチの予防及び／又は治療薬 | |
| JP2020514282A5 (enExample) | ||
| Zhang et al. | The safety and efficacy of intranasal dexmedetomidine during electrochemotherapy for facial vascular malformation: a double-blind, randomized clinical trial | |
| JP2013518124A5 (enExample) | ||
| KR20190073365A (ko) | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2010514834A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2018536638A5 (enExample) | ||
| JP2008540405A5 (enExample) | ||
| Chen et al. | Efficacy and Safety of Mepolizumab as an Add-on Therapy in Chinese Patients With Severe Eosinophilic Asthma: A Randomized, Double-Blind, Parallel Group Phase 3 Study | |
| Yeh et al. | Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels | |
| Aftanas et al. | Xenon in sub-anesthetic doses for treatment of major depression: a proof-of-concept placebo-controlled pilot study | |
| RU2018144248A (ru) | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта | |
| JP2017511307A5 (enExample) | ||
| JP2003535133A5 (enExample) | ||
| CN104687927A (zh) | 一种具有降压作用的保健药枕 | |
| Chua et al. | Acute severe asthma: triage, treatment and thereafter | |
| JP6028968B2 (ja) | 抗インフルエンザウイルス剤 |